Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
44.19 USD | -0.02% | +4.22% | -40.04% |
May. 15 | QuidelOrtho Opens New Distribution Center in Pedricktown, NJ | CI |
May. 14 | Activist Jana Partners built position in QuidelOrtho in first quarter, sources say | RE |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- The company appears to be poorly valued given its net asset value.
- The company has a low valuation given the cash flows generated by its activity.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- Low profitability weakens the company.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-40.04% | 2.96B | C+ | ||
-27.52% | 16.33B | A | ||
+15.16% | 1.82B | - | ||
-6.86% | 1.55B | - | ||
+38.67% | 1.41B | B+ | ||
-15.36% | 976M | - | ||
-26.08% | 846M | - | C- | |
+3.53% | 811M | - | ||
-24.63% | 631M | B+ | ||
+23.58% | 593M | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- QDEL Stock
- Ratings QuidelOrtho Corporation